ReviewVascular health and risk management2010
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Review in Vascular health and risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04730882 (Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Postprandial Hyperglycemia on Vasculature in Type 1 Diabetes and Healthy Adults
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Antioxidant and anti-inflammatory properties of ginsenoside Rg1 for hyperglycemia in type 2 diabetes mellitus: systematic reviews and meta-analyses of animal studies.Frontiers in pharmacology · 2023Pooled it
- Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.BMJ open diabetes research & care · 2021Trial
- Probiotic fruit beverages with different polyphenol profiles attenuated early insulin response.Nutrition journal · 2018Trial
- Slow post meal walking reduces the blood glucose response: an exploratory study in female Pakistani immigrants.Journal of immigrant and minority health · 2012Trial
- Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes.Diabetes · 2012Trial
- Dietary fiber, carbohydrate quality and quantity, and mortality risk of individuals with diabetes mellitus.PloS one · 2012Trial
- Dietary glycemic load and glycemic index and risk of coronary heart disease and stroke in Dutch men and women: the EPIC-MORGEN study.PloS one · 2011Trial
- Review
- Article
- CGM-derived postprandial glucose with IcoSema versus other insulin regimens: aEClinicalMedicine · 2026Article
- Glucose variability measured by continuous glucose monitoring is associated with skin autofluorescence: the Maastricht Study.Diabetologia · 2025Article
- Machine learning prediction of intestinal α-glucosidase inhibitors using a diverse set of ligands: a drug repurposing effort with drugBank database screening.In silico pharmacology · 2025Article
- Wireless, Programmable, and Refillable Hydrogel Bioelectronics for Enhanced Diabetic Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Effect of Honey on Postprandial Hyperglycemia in Alloxan-Induced Diabetic Rats.Archives of Razi Institute · 2024Article
- Exploring Beneficial Properties of Haskap Berry Leaf Compounds for Gut Health Enhancement.Antioxidants (Basel, Switzerland) · 2024Article
- Anti-diabetic compounds fromHeliyon · 2024Article
- Impact of gut microbiota and associated mechanisms on postprandial glucose levels in patients with diabetes.Journal of translational internal medicine · 2023Article
- Sodium butyrate inhibits high glucose-induced inflammation by controlling the acetylation of NF-κB p65 in human monocytes.Nutrition research and practice · 2023Article
- A Comprehensive Review with Future Prospects on the Medicinal Properties and Biological Activities ofEvidence-based complementary and alternative medicine : eCAM · 2023Review
- Flavonoids and Phenols, the Potential Anti-Diabetic Compounds fromMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, anti-hyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.